What the FDA labels say about taking them together
Azacitidine and olutasidenib
Olutasidenib's FDA label of November 5, 2025 names azacitidine in its warnings and precautions section; the azacitidine labels PlainMeds reads (3) do not name olutasidenib.
Check it at the source: the azacitidine FDA label on DailyMed (effective January 29, 2024, Celgene Corporation); the olutasidenib FDA label on DailyMed (effective November 5, 2025, Rigel Pharmaceuticals, Inc.).
What does the azacitidine label say about olutasidenib?
Azacitidine's label (effective January 29, 2024) and its 2 other brand-application labels do not name olutasidenib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VIDAZA), NDA050794 (Bristol-Myers), as published by Celgene Corporation, effective January 29, 2024 (SPL set 3495a71a-cc04-4776-851f-f185956f32af), via openFDA; the full label on DailyMed
What does the olutasidenib label say about azacitidine?
Olutasidenib label, warnings and precautionsOne patient treated with REZLIDHIA in combination with azacitidine in the clinical trial, a combination for which REZLIDHIA is not indicated, died from complications of drug-induced liver injury.
Source: FDA drug label (REZLIDHIA), Rigel Pharmaceuticals, Inc., effective November 5, 2025 (SPL set 4a0c7c8b-b95f-455d-9600-b7351e4397fe), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Azacitidine | Olutasidenib | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once